Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOUNCE THERAPEUTICS, INC.

(JNCE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Update: Jounce Therapeutics to Get $25 Million From Gilead Sciences After FDA Clears Cancer Therapy for Trials

06/15/2021 | 02:53pm EDT


ę MT Newswires 2021
All news about JOUNCE THERAPEUTICS, INC.
07/29Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Hos..
GL
07/07JOUNCE THERAPEUTICS : to Participate in William Blair's Biotech Focus Conference
AQ
06/25JOUNCE THERAPEUTICS, INC.(NASDAQGS : JNCE) dropped from Russell 2000 Defensive I..
CI
06/25JOUNCE THERAPEUTICS, INC.(NASDAQGS : JNCE) dropped from Russell 2000 Value-Defen..
CI
06/23JOUNCE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders ..
AQ
06/23Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Ex..
GL
06/16Jounce Therapeutics to Host Virtual R&D Day on June 23, 2021
GL
06/15UPDATE : Jounce Therapeutics to Get $25 Million From Gilead Sciences After FDA C..
MT
06/15Jounce Therapeutics Shares Rise 13% on IND Clearance for Cancer Treatment
DJ
06/15JOUNCE THERAPEUTICS : Set for $25 Million Milestone Payment from Gilead After In..
MT
More news
Financials (USD)
Sales 2021 25,8 M - -
Net income 2021 -85,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,85x
Yield 2021 -
Capitalization 262 M 262 M -
Capi. / Sales 2021 10,1x
Capi. / Sales 2022 12,3x
Nbr of Employees 128
Free-Float 81,7%
Chart JOUNCE THERAPEUTICS, INC.
Duration : Period :
Jounce Therapeutics, Inc. Technical Analysis Chart | JNCE | US4811161011 | MarketScreener
Technical analysis trends JOUNCE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 5,13 $
Average target price 16,03 $
Spread / Average Target 212%
EPS Revisions
Managers and Directors
Richard Murray President, Chief Executive Officer & Director
Kimberlee Cobleigh Drapkin Chief Financial Officer & Treasurer
Perry A. Karsen Chairman
Elizabeth G. Trehu Chief Medical Officer
Stephen Farrand Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
JOUNCE THERAPEUTICS, INC.-27.00%265
GILEAD SCIENCES, INC.17.32%87 579
BIONTECH SE331.56%84 970
WUXI APPTEC CO., LTD.41.52%71 929
REGENERON PHARMACEUTICALS19.46%60 737
VERTEX PHARMACEUTICALS-15.36%51 899